Idiopathic pulmonary fibrosis

32 trials 8 recruiting MedDRA PT
32 Registered trials
8 Recruiting
28 Unique sponsors
27 Unique IMPs
26 Commercial trials
Drug classes (ATC)
— ATC code not specified 24
N Neurology/Psychiatry (ATC N) 1
L Oncology (ATC L) 2
B Haematology (ATC B) 2
H Endocrinology (ATC H) 1
R Respiratory (ATC R) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 18 substances
Monoclonal antibody (immune) 3 substances
Supportive / diluent 2 substances
Corticosteroid 2 substances
Kinase inhibitor 1 substance
Monoclonal antibody 1 substance
Phase III: 4 Phase II/III: 1 Phase II: 18 Phase I: 3 Phase I (Other): 5 Phase I (First in Human): 1

Filter these 32 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 32 trials

Phase III

4 trials
  • Boehringer Ingelheim International GmbH Commercial
    1-[[(5R)-2-[4-(5-CHLORO-2-PYRIMIDINYL)-1-PIPERIDINYL]-6,7- DIHYDRO-5-OXIDOTHIENO[3,2-D]PYRIMIDIN-4- YL]AMINO]-CYCLOBUTANEMETHANOL; BI 1015550
    2023-507353-15-00 20 countries 2024 n=551
    Recruiting
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    ADMILPARANT
    2023-503697-21-01 15 countries 2024 n=239
    Recruiting
  • United Therapeutics Corp. Commercial
    TREPROSTINIL
    2024-514761-19-00 7 countries 2023 n=382 Orphan
    Ended
  • Hospices Civils De Lyon Academic
    NINTEDANIB; PIRFENIDONE
    2024-511427-34-00 1 country 2020 n=378 Orphan
    Ended

Phase II/III

1 trial
  • Pliant Therapeutics Inc. Commercial
    BEXOTEGRAST
    2023-506185-31-00 11 countries 2024 n=318 Orphan
    Ended

Phase II

18 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    HUMANISED IGG1 LALAPS-YTE MONOCLONAL ANTIBODY AGAINST LYSOPHOSPHATIDIC ACID RECEPTOR 1
    2024-518013-25-00 11 countries n=85
    Pending
  • Avalyn Pharma Inc. Commercial
    NINTEDANIB
    2025-523431-19-00 3 countries 2026 n=96
    Recruiting
  • Calluna Pharma AS Commercial
    CAL101
    2024-518339-12-00 7 countries 2025 n=87
    Ended
  • Chiesi Farmaceutici S.p.A. Commercial
    ZAMPILIMAB
    2024-514246-37-00 10 countries n=95
    Pending
  • Genentech Inc. Commercial
    VIXARELIMAB
    2022-502828-42-00 8 countries 2023 n=134
    Ended
  • Generate Biomedicines Inc. Commercial
    TALADEGIB
    2024-511754-41-00 6 countries 2025 n=140 Orphan
    Ended
  • Horizon Therapeutics Ireland Designated Activity Company Commercial
    FIPAXALPARANT
    2023-509784-24-00 6 countries 2022 n=17 Orphan
    Ended
  • Mediar Therapeutics Inc. Commercial
    GLUCOSE MONOHYDRATE; MTX-463; SODIUM CHLORIDE
    2025-521278-32-00 6 countries 2025 n=58
    Recruiting
  • Modern Biosciences Limited Commercial
    MBS2320
    2023-504418-30-00 6 countries 2023 n=156
    Ended
  • Novartis Pharma AG Commercial
    LTP001
    2023-508729-28-00 4 countries 2023 n=36
    Ended
  • Puretech Lyt 100 Inc. Commercial
    DEUPIRFENIDONE
    2024-511330-13-00 2 countries 2023 n=14
    Ended
  • Rein Therapeutics Inc. Commercial
    LTI-03
    2025-520715-13-00 2 countries 2026 n=28 Orphan
    Recruiting
  • Syndax Pharmaceuticals Inc. Commercial
    AXATILIMAB
    2022-502954-15-00 8 countries 2024 n=141
    Ended
  • Trevi Therapeutics Inc. Commercial
    NALBUPHINE HYDROCHLORIDE
    2023-505296-72-00 5 countries 2023 n=90
    Ended
  • Vicore Pharma AB Commercial
    BULOXIBUTID
    2023-509069-19-00 6 countries 2024 n=94 Orphan
    Ended
  • GIE Groupe hospitalier Paris Saint-Joseph/Vinci Academic
    METHYLPREDNISOLONE HYDROGEN SUCCINATE; PREDNISONE
    2024-514799-42-00 1 country 2024 n=110
    Recruiting
  • Philipps-Universitaet Marburg Academic
    PHOSPHOLIPID FRACTION, BOVINE LUNG
    2023-508544-22-00 1 country n=20
    Pending
  • Philipps-Universitaet Marburg Academic
    TEZEPELUMAB
    2024-510884-51-00 1 country 2025 n=39
    Recruiting

Phase I

3 trials
  • Chiesi Farmaceutici S.p.A. Commercial
    IMP not specified
    2024-515442-17-00 1 country 2024 n=156
    Ended
  • Gat Therapeutics S.L. Commercial
    IMP not specified
    2023-504426-19-00 1 country 2024 n=52
    Ended
  • The Scripps Research Institute Academic
    IMP not specified
    2023-510456-23-00 1 country 2024 n=112
    Ended

Phase I (Other)

5 trials
  • Cereno Scientific AB Commercial
    IMP not specified
    2025-524883-39-00 1 country n=14
    Pending
  • Enlitisa (Shanghai) Pharmaceutical Co. Ltd. Commercial
    IMP not specified
    2023-506912-41-00 1 country 2024 n=48
    Ended
  • Vicore Pharma AB Commercial
    IMP not specified
    2025-520702-35-00 1 country 2025 n=30
    Ended
  • Vicore Pharma AB Commercial
    IMP not specified
    2026-526135-18-00 1 country 2026 n=24
    Recruiting
  • Centre Hospitalier Universitaire De Dijon Academic
    IMP not specified
    2024-515303-19-00 1 country 2023 n=20
    Ended

Phase I (First in Human)

1 trial
  • Arrowhead Pharmaceuticals Inc. Commercial
    IMP not specified
    2023-504964-41-00 3 countries 2024 n=15
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Vicore Pharma AB Commercial 3 Phase I (Other), Phase II 1
Chiesi Farmaceutici S.p.A. Commercial 2 Phase I, Phase II 0
Philipps-Universitaet Marburg Academic 2 Phase II 1
Gat Therapeutics S.L. Commercial 1 Phase I 0
Pliant Therapeutics Inc. Commercial 1 Phase II/III 0
Cereno Scientific AB Commercial 1 Phase I (Other) 0
Enlitisa (Shanghai) Pharmaceutical Co. Ltd. Commercial 1 Phase I (Other) 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase II 0
Avalyn Pharma Inc. Commercial 1 Phase II 1
Calluna Pharma AS Commercial 1 Phase II 0
Genentech Inc. Commercial 1 Phase II 0
Generate Biomedicines Inc. Commercial 1 Phase II 0
Horizon Therapeutics Ireland Designated Activity Company Commercial 1 Phase II 0
Mediar Therapeutics Inc. Commercial 1 Phase II 1
Modern Biosciences Limited Commercial 1 Phase II 0
Novartis Pharma AG Commercial 1 Phase II 0
Puretech Lyt 100 Inc. Commercial 1 Phase II 0
Rein Therapeutics Inc. Commercial 1 Phase II 1
Syndax Pharmaceuticals Inc. Commercial 1 Phase II 0
Trevi Therapeutics Inc. Commercial 1 Phase II 0
New trials by year
2020
1
2022
1
2023
7
2024
11
2025
5
2026
3
← All indication landscapes